ID
16973
Description
Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study; ODM derived from: https://clinicaltrials.gov/show/NCT00216593
Link
https://clinicaltrials.gov/show/NCT00216593
Keywords
Versions (2)
- 8/17/16 8/17/16 -
- 8/17/16 8/17/16 -
Uploaded on
August 17, 2016
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Dementia NCT00216593
Eligibility Dementia NCT00216593
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
ID.5
Data type
boolean
Description
ID.6
Data type
boolean
Description
ID.7
Data type
boolean
Description
ID.8
Data type
boolean
Description
ID.9
Data type
boolean
Similar models
Eligibility Dementia NCT00216593
- StudyEvent: Eligibility
C0205082 (UMLS CUI [1,2])
C0205329 (UMLS CUI [1,2])
C0338656 (UMLS CUI [2,1])
C0205329 (UMLS CUI [2,2])
C0412585 (UMLS CUI [2])
C0412675 (UMLS CUI [3])
C1269765 (UMLS CUI [1,2])
C0578670 (UMLS CUI [2,1])
C0439846 (UMLS CUI [2,2])
C0042789 (UMLS CUI [3,1])
C0205410 (UMLS CUI [3,2])
C0039593 (UMLS CUI [3,3])
C1321605 (UMLS CUI [3,4])
C0018767 (UMLS CUI [4,1])
C0205410 (UMLS CUI [4,2])
C0039593 (UMLS CUI [4,3])
C1321605 (UMLS CUI [4,4])